ArticleClinical kidney journal2025
Serum proteome analysis detects early molecular signatures of disease progression in IgA nephropathy.
Article in Clinical kidney journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immunoglobulin A nephropathy (IgAN) is a common cause of chronic kidney disease (CKD) and identifying early molecular signatures is crucial for IgAN risk stratification and timely intervention. In this study we used serum proteomics to investigate molecular differences between IgAN patients who progressed and those who remained stable before separation in kidney function became apparent. Methods: Serum samples from 40 adults with biopsy-proven IgAN were analysed and classified as progressors (PRs; Results: Fifty-two proteins showed a significant differential abundance between PRs and NPs. Enrichment analysis revealed dysregulation in complement cascade, extracellular matrix signalling and renin-angiotensin system in PRs compared with NPs. Finally, the random forest model on this protein set achieved an accuracy of 85.0% and identified NCAM1, F7, ARG1, CLU and ANXA5 among the most important predictors. Conclusions: Serum proteomic profiling identified early molecular differences between PR and NP IgAN patients. These findings support the utility of serum proteomics for early risk stratification in IgAN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.